Cargando…

Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways

In recent years, many therapeutic advances have been made in the management of castration-resistant prostate cancer, with the development and approval of many new drugs. The androgen receptor (AR) is the main driver in prostate cancer growth and progression and the most effective therapeutic agents...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bungaro, Maristella, Buttigliero, Consuelo, Tucci, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992570/ https://www.ncbi.nlm.nih.gov/pubmed/35582226 http://dx.doi.org/10.20517/cdr.2020.42

Ejemplares similares

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review
por: Marandino, Laura, et al.
Publicado: (2020)

Arsenic and Prostate Cancer: Acquiring Androgen Independence
por: Tibbetts, John
Publicado: (2005)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
por: Turco, Fabio, et al.
Publicado: (2023)

Local for advanced, is this a paradox?
por: Bungaro, Maristella, et al.
Publicado: (2021)

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
por: Zichi, Clizia, et al.
Publicado: (2017)

Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer
por: Saito, Yohei, et al.
Publicado: (2021)

Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer
por: Lo Iacono, Marco, et al.
Publicado: (2016)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

P-Glycoprotein and Androgen Receptor Expression Reveals Independence of Canine Prostate Cancer from Androgen Hormone Stimulation
por: Cavalca, Alexandre Matheus Baesso, et al.
Publicado: (2022)

Hormones and prostate carcinogenesis: Androgens and estrogens
por: Bosland, Maarten C., et al.
Publicado: (2011)

Mechanisms of Androgen-Independent Prostate Cancer
por: Saraon, Punit, et al.
Publicado: (2014)

Mechanisms of Acquired Androgen Independence during Arsenic-Induced Malignant Transformation of Human Prostate Epithelial Cells
por: Benbrahim-Tallaa, Lamia, et al.
Publicado: (2007)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
por: Rajaram, Pravien, et al.
Publicado: (2020)

COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery
por: Bungaro, Maristella, et al.
Publicado: (2022)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling
por: D'Antonio, Jason M., et al.
Publicado: (2010)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
por: Wen, Simeng, et al.
Publicado: (2020)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
por: Caffo, O., et al.
Publicado: (2020)

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
por: Rajan, Prabhakar, et al.
Publicado: (2014)

AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
por: Winther, Mads Dochedahl, et al.
Publicado: (2020)

Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs
por: Turco, Fabio, et al.
Publicado: (2022)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Regulation of expression of Na(+),K(+)-ATPase in androgen-dependent and androgen-independent prostate cancer
por: Blok, L J, et al.
Publicado: (1999)

Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer
por: Abd. Wahab, Nurul Azwa, et al.
Publicado: (2020)

The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications
por: Torabinejad, Sepehr, et al.
Publicado: (2023)

Anticancer Imidazoacridinone C-1311 is Effective in Androgen-Dependent and Androgen-Independent Prostate Cancer Cells
por: Niemira, Magdalena, et al.
Publicado: (2020)

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
por: Roshani, Hossain, et al.
Publicado: (2021)

Sulfur inhibits the growth of androgen-independent prostate cancer in vivo
por: DUAN, FEI, et al.
Publicado: (2015)

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia
por: Hata, Junya, et al.
Publicado: (2023)

Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
por: Tamada, Satoshi, et al.
Publicado: (2018)

Maximal androgen blockade for advanced prostate cancer
por: Mukha, Rajiv Paul, et al.
Publicado: (2010)

Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
por: Ulm, Michael, et al.
Publicado: (2019)

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
por: Kregel, Steven, et al.
Publicado: (2020)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer
por: Li, Liuxun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_esq66jlqdb7g38knhdkntbf8fa